source
- Merck and Moderna report success in late-stage trial of personalized mRNA cancer vaccineMerck and Moderna announced that their personalized mRNA cancer vaccine achieved its primary endpoint in a randomized late-stage trial, marking the first demonstration that such an approach can be…
- Regeneron's Pasatru receives FDA approval for ultra-rare bone-growth disease FOPRegeneron Pharmaceuticals has secured FDA approval for Pasatru, a therapy aimed at treating fibrodysplasia ossificans progressiva (FOP), an ultra‑rare condition in which bone forms in soft tissues.…